Myfembree® (relugolix/estradiol/norethindrone acetate) – New indication
August 5, 2022 - Pfizer announced the FDA approval of Myfembree (relugolix/estradiol/norethindrone acetate), for premenopausal women for the management of moderate to severe pain associated with endometriosis.
Download PDF
